Connect with us

Technology

Evogene and Tel Aviv University’s Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery

Published

on

Supporting Israel’s Academic Innovation Ecosystem: BCDD to Provide World-Class Experimental Infrastructure, Evogene to Deliver Computational Chemistry and AI Capabilities

REHOVOT, ISRAEL and TEL AVIV, ISRAEL, July 8, 2026 /PRNewswire/ — Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational chemistry company focused on the generative design of small molecules for the pharmaceutical and agricultural industries, and the Blavatnik Center for Drug Discovery (BCDD) at Tel Aviv University, today announced a strategic joint initiative aimed at accelerating the growth, development, and success of innovation originating from Israel’s academic research ecosystem and focused on small-molecule drug discovery. This collaboration agreement was facilitated by Ramot, Tel Aviv University’s tech transfer company.

 

 

 

The initiative is designed to support scientific entrepreneurs and research teams that possess deep biological understanding of novel disease targets but often face significant challenges in translating these discoveries into viable drug development programs. By combining BCDD’s advanced experimental infrastructure and translational drug discovery capabilities with Evogene’s AI-driven computational chemistry generative engine, ChemPass AI™, the collaboration seeks to create a powerful acceleration framework that bridges the gap between biological insight and drug candidate development.

Many promising academic discoveries fail to progress due to the lack of integrated capabilities required for early-stage drug discovery. This joint initiative directly addresses these challenges by providing entrepreneurs with access to both computational and experimental resources under a coordinated development framework.

At the heart of the collaboration is an integrated Design-Make-Test-Analyze (DMTA) workflow. Together, Evogene and the BCDD will identify and evaluate promising projects emerging from Israeli academic institutions and entrepreneurial ventures. Selected programs will benefit from Evogene’s proprietary ChemPass AI™ generative engine and computational chemistry expertise for the design and optimization of novel small molecules, while the BCDD will provide experimental validation, screening capabilities, and translational development support through its state-of-the-art infrastructure. Together, driven by ChemPass AI™ this integrated workflow is designed to improve development efficiency, reduce early-stage risk and increase the likelihood of commercial success for emerging drug candidates.

Mr. Ofer Haviv, President and CEO of Evogene, said: “Israel’s academic institutions generate world-class discoveries and novel therapeutic targets. However, many entrepreneurs and researchers face significant hurdles in transforming these scientific insights into viable drug development programs. Through this collaboration with the Blavatnik Center for Drug Discovery, we are creating a unique framework that combines advanced AI-driven computational chemistry with world-class experimental validation capabilities. This collaboration represents an excellent way to broaden the pipeline of drug candidates developed by Evogene’s unique technology. Researchers focused on biological targets, particularly molecular glues and complex proteins, and interested in identifying small-molecule therapeutics are invited to contact the Blavatnik Institute. We look forward to identifying suitable projects for potential joint support.”

Leah Klapper, Managing Director of the Blavatnik Center for Drug Discovery, said: “The Blavatnik Center for Drug Discovery was established to advance pioneering medical research from the lab to patient treatment. Our mission has always been to bridge the gap between outstanding academic science and real-world therapeutic innovation. By partnering with Evogene, and leveraging their cutting-edge ChemPass AI™ engine, we can provide researchers and entrepreneurs with a comprehensive drug discovery pipeline. This platform uniquely combines deep biological expertise, experimental validation, and advanced computational chemistry. We believe this collaboration will significantly strengthen the ability of academic-originated ventures to translate breakthrough discoveries into successful therapeutic programs, ultimately improving patient outcomes.”

About Evogene Ltd.

Evogene Ltd. (Nasdaq/TASE: EVGN) is a pioneering company in computational specializing in the generative design of small molecules for drug development and ag-chemical products. At the core of its technology is ChemPass AI™ a proprietary generative AI designed to explore vast chemical space and generate novel, highly potent small molecules optimized across multiple critical parameters. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on products for the pharmaceutical and agricultural industries, driven by the integration of scientific innovation with real-world industry needs.

For more information, please visit www.evogene.com.

About the Blavatnik Center for Drug Discovery (BCDD)

The Blavatnik Center for Drug Discovery at Tel Aviv University is a leading translational research center dedicated to advancing promising academic discoveries toward therapeutic development. The center provides state-of-the-art infrastructure, scientific expertise, and industry-oriented drug discovery capabilities that enable researchers to transform innovative biological insights into potential drug candidates.

About Ramot at Tel Aviv University Ramot is the tech transfer company of Tel Aviv University, managing the university’s intellectual property to translate academic research into commercial products and startup companies. Ramot fosters strategic collaborations and licensing agreements, bridging the gap between scientific discoveries and global industries across a wide range of fields.

Forward-Looking Statements: 

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 relating to future events. These statements may be identified by words such as “may,” “could,” “expects,” “hopes,” “intends,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates,” “demonstrates”, “designed to,” “intended to,” “with the goal of,” or words of similar meaning. For example, Evogene uses forward-looking statements in this press release when it discusses: the collaboration success in creating viable drug development programs and drug candidate development, the success of the collaboration with accelerating development, reduce risk, and improving the probability of bringing impactful therapies to patients, the collaboration success with strengthening the ability of academic-originated ventures to translate breakthrough discoveries into successful therapeutic programs and ultimately improve patient outcomes. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, the aftermath of the recent war between Israel and each of (i) the terrorist groups, Hamas and Hezbollah, (ii) Iran, and (iii) other regional terrorist groups supported by Iran, and any potential destabilizations in Israel, neighboring territories or the Middle East region, and those risk factors contained in Evogene’s reports filed with the applicable securities authority. In addition, Evogene and its subsidiaries rely, and expect to continue to rely, on third parties to conduct certain activities, such as their and pre-clinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, Evogene and its subsidiaries may experience significant delays in the conduct of their activities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

Investor Relations Contact:
ir@evogene.com
Tel: +972-8-9311901

Logo: https://mma.prnewswire.com/media/1947468/Evogene.jpg
Logo: https://mma.prnewswire.com/media/3004809/6023712/Blavatnik.jpg

View original content:https://www.prnewswire.com/news-releases/evogene-and-tel-aviv-universitys-blavatnik-center-for-drug-discovery-announce-joint-initiative-to-accelerate-ai-driven-small-molecule-drug-discovery-302820619.html

SOURCE Evogene; Blavatnik Center for Drug Discovery

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

HealthTree Foundation Announces the Appointment of Lisa Gray to Its Board of Directors

Published

on

By

SALT LAKE CITY, July 10, 2026 /PRNewswire/ — The HealthTree Foundation, a nonprofit organization dedicated to advancing cures for multiple myeloma and other blood cancers through patient empowerment, research, and education, today announced the appointment of Lisa Gray, an accomplished fundraising strategist and nonprofit leader, to its Board of Directors.

Lisa brings nearly 30 years of experience advancing philanthropy across national health and education organizations. Throughout her career, she has led transformational development initiatives and teams that strengthened mission-driven organizations and expanded their capacity to deliver patient care and drive scientific discovery. Her leadership has been marked by innovative strategies to diversify and strengthen fundraising programs and foster a vibrant culture of philanthropy that accelerates mission delivery and sustainable revenue growth.

Most recently, Lisa served as Senior Vice President for Development at the Pancreatic Cancer Action Network, where she led the development program and staff, generating $20M+ annually. Prior to that, she held a senior vice president role at Blood Cancer United (formerly the Leukemia & Lymphoma Society), helping to drive revenue growth and deepen philanthropic support.

Diagnosed with multiple myeloma in 2023, Lisa has since dedicated time to supporting fellow patients and advancing research that improves outcomes across the myeloma community. Her dual perspective—as both a seasoned philanthropic leader and a patient—will bring valuable insight to HealthTree’s expanding mission.

“We are honored to welcome Lisa to the HealthTree Board of Directors,” said Jenny Ahlstrom, founder and CEO of the HealthTree Foundation. “Her exceptional track record in philanthropic leadership, combined with her personal experience as a myeloma patient, gives her a unique ability to guide and inspire our work. Lisa’s voice will be an invaluable asset as we continue to drive innovation and accelerate cures for patients everywhere.”

About HealthTree Foundation HealthTree Foundation is a nonprofit organization dedicated to helping cancer patients better navigate their healthcare journey by providing tools, education, and access to their complete medical records. Through its technology platform, HealthTree empowers patients to take control of their health data, improve outcomes, and accelerate research.

View original content to download multimedia:https://www.prnewswire.com/news-releases/healthtree-foundation-announces-the-appointment-of-lisa-gray-to-its-board-of-directors-302823076.html

SOURCE HealthTree Foundation

Continue Reading

Technology

Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Action

Published

on

By

TEANECK, N.J., July 10, 2026 /PRNewswire/ — Cognizant (Nasdaq: CTSH) has released the following notice:

HERMAN JONES LLP
SERINA M. VASH
153 Central Avenue #131
Westfield, NJ 07090
svash@hermanjones.com
Telephone: (404) 504-6516
Facsimile: (404) 504-6501

[Additional Counsel on Signature Page]

Attorneys for Plaintiff

UNITED STATES DISTRICT COURT 
FOR THE DISTRICT OF NEW JERSEY

VISWANATHA PALEMPALLI,

Derivatively on Behalf of COGNIZANT
TECHNOLOGY SOLUTIONS CORPORATION,

Plaintiff,

v.


MICHAEL PATSALOS-FOX, JOHN

N. FOX, JR., MAUREEN BREAKIRON-
EVANS, LEO S. MACKAY, JR., ZEIN
ABDALLA, FRANCISCO D’SOUZA,
KAREN MCLOUGHLIN, RAJEEV MEHTA,
GORDON J. COBURN, STEVEN
SCHWARTZ, RAMAKRISHNAN
CHANDRASEKARAN, JOHN E. KLEIN,
JONATHAN CHADWICK, THOMAS M.
WENDEL, LAKSHMI NARAYANAN, and
ROBERT E. WEISSMAN,

Defendants,


-and-


COGNIZANT TECHNOLOGY SOLUTIONS
CORPORATION, a

Delaware Corporation,

           Nominal Defendant.                                   

 

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

Case No. 2:21-cv-12025-EP-SDA


SUMMARY NOTICE OF PENDENCY
AND PROPOSED SETTLEMENT OF
STOCKHOLDER DERIVATIVE ACTION


EXHIBIT B-2

TO: ALL OWNERS OF THE COMMON STOCK OF COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION (“COGNIZANT” OR THE “COMPANY”) CURRENTLY AND AS OF NOVEMBER 25, 2025:

THIS NOTICE RELATES TO THE PENDENCY AND PROPOSED SETTLEMENT OF STOCKHOLDER DERIVATIVE LITIGATION. PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY. IF YOU ARE A COGNIZANT STOCKHOLDER, THIS NOTICE CONTAINS IMPORTANT INFORMATION ABOUT YOUR RIGHTS.

THIS DERIVATIVE ACTION IS NOT A “CLASS ACTION.” THUS, THERE IS NO COMMON FUND UPON WHICH YOU CAN MAKE A CLAIM FOR MONETARY PAYMENT. IF YOU DO NOT OBJECT TO THE TERMS OF THE PROPOSED SETTLEMENT, THE AMOUNT OF ATTORNEYS’ FEES AND EXPENSES, OR THE AMOUNT OF THE SERVICE AWARD DESCRIBED IN THIS NOTICE, YOU ARE NOT OBLIGATED TO TAKE ANY ACTION.

PLEASE TAKE NOTICE that the parties to the above-captioned stockholder derivative action have reached an agreement to settle the derivative claims brought on behalf of and for the benefit of Cognizant.

The terms of the settlement are set forth in a Stipulation and Agreement of Settlement dated November 25, 2025 (the “Stipulation”).1 This notice should be read in conjunction with, and is qualified in its entirety by reference to, the text of the Stipulation, which has been filed with the U.S. District Court for the District of New Jersey. A link to the text of the Stipulation and the full-length Long-Form Notice of Pendency and Proposed Settlement of Stockholder Derivative Action may be found on the “Investors” page of Cognizant’s website at http://investors.cognizant.com.

1 All capitalized terms herein have the same meanings as set forth in the Stipulation.

Under the terms of the Stipulation, as a part of the proposed Settlement, the Defendants shall cause their insurers to pay to Cognizant a sum of $5.5 million (the “Settlement Fund”), minus the court-approved Fee and Expense Amount. Defendants acknowledge that Plaintiff’s and Plaintiff’s Counsel’s demand, litigation, and settlement efforts caused Defendants’ insurers to agree to make the cash payment to Cognizant.

In consideration of the substantial benefit conferred upon Cognizant as a direct result of the Settlement and the efforts of Plaintiff and Plaintiff’s Counsel in the Derivative Action, Plaintiff’s Counsel will request Court approval of an award of attorneys’ fees and expenses not to exceed $1,830,000 (or approximately 33% of the Settlement Fund). Plaintiff’s Counsel also will apply to the Court for a service award of up to $15,000 to Plaintiff, subject to Court approval, which will be paid from any approved Fee and Expense Amount.

A hearing will be held on SEPTEMBER 14, 2026, at 11:00 a.m. before the Honorable Stacey D. Adams of the United States District Court for the District of New Jersey at the Frank R. Lautenberg Post Office and U.S. Courthouse, 2 Federal Square, Courtroom 9, Newark, New Jersey 07102 (the “Settlement Hearing”), at which the Court will determine whether to approve the Settlement.

Any Current Cognizant Stockholder has a right, but is not required, to appear and to be heard at the Settlement Hearing, providing that he, she, or it is a stockholder of record or beneficial owner of Cognizant common stock and was a stockholder of record or beneficial owner of Cognizant common stock as of November 25, 2025. Any Current Cognizant Stockholder who satisfies this requirement may enter an appearance through counsel of such stockholder’s own choosing and at such stockholder’s own expense, or may appear on his or her own. However, you shall not be heard at the Settlement Hearing unless, no later than August 31, 2026, you have filed with the Court a written notice of objection containing the following information:

Your name, legal address, and telephone number;The case name and number (Palempalli v. Patsalos-Fox, et al., Case No. 2:21-cv-12025-EP-SDA);Proof of being a Cognizant stockholder currently and as of November 25, 2025;The date(s) you acquired your Cognizant stock;A statement of each objection being made;Notice of whether you intend to appear at the Settlement Hearing (you are not required to appear); andCopies of any papers you intend to submit to the Court, along with the names of any witness(es) you intend to call to testify at the Settlement Hearing and the subject(s) of their testimony.

If you wish to object to the proposed Settlement, you must file the written objection described above with the Court on or before August 31, 2026. All written objections and supporting papers must be filed with the Clerk of the Court, U.S. District Court for the District of New Jersey, at the Martin Luther King Building and U.S. Courthouse, 50 Walnut Street, Newark, N.J. 07101, and served by that date on each of the following Settling Parties’ counsel:

Counsel for Plaintiff:


Stephen J. Oddo

ROBBINS LLP

5060 Shoreham Place, Suite 300

San Diego, CA 92122

Counsel for Defendants:


Daniel Roeser

Charles A. Brown

GOODWIN PROCTER LLP

The New York Times Building

620 Eighth Avenue

New York, NY 10018

James Holsey Keale

TANENBAUM KEALE LLP

Three Gateway Center, Suite 1301

100 Mulberry Street

Newark, New Jersey 07102

Nina Yadava

Sarah D. Efronson

JONES DAY

250 Vesey Street

New York, New York 10281

Andrew J. Ehrlich

Alison R. Benedon

PAUL, WEISS, RIFKIND, WHARTON &
GARRISON LLP

1285 Avenue of the Americas

New York, New York 10019

YOUR WRITTEN OBJECTIONS MUST BE POSTMARKED OR ON FILE WITH THE CLERK OF THE COURT NO LATER THAN AUGUST 31, 2026.

Only stockholders who have filed and delivered valid and timely written notices of objection will be entitled to be heard at the Settlement Hearing unless the Court orders otherwise. If you fail to object in the manner and within the time prescribed above, you shall be deemed to have waived your right to object (including the right to appeal) and shall forever be barred, in this proceeding or in any other proceeding, from raising such objection(s).

Inquiries may be made to Plaintiff’s Counsel: Robbins LLP, 5060 Shoreham Place, Suite 300, San Diego, California 92122, telephone: (619) 525-3990.

PLEASE DO NOT CONTACT THE COURT
OR DEFENDANTS REGARDING THIS NOTICE

DATED: June 29, 2026

BY ORDER OF THE COURT

U.S. DISTRICT COURT OF NEW JERSEY

About Cognizant
Cognizant (NASDAQ: CTSH) is an AI builder and technology services provider, building the bridge between AI investment and enterprise value by building full-stack AI solutions for our clients. Our deep industry, process and engineering expertise enables us to build an organization’s unique context into technology systems that amplify human potential, realize tangible returns and keep global enterprises ahead in a fast-changing world. See how at www.cognizant.ai or @cognizant.

Investor Relations Contact:
Tyler Scott, SVP, Investor Relations, (551) 220-8246, tyler.scott@cognizant.com

Media Contact:
Jeff DeMarrais, SVP Corporate Communications, (475) 223-2298, jeff.demarrais@cognizant.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/summary-notice-of-pendency-and-proposed-settlement-of-stockholder-derivative-action-302822902.html

SOURCE Cognizant Technology Solutions Corporation

Continue Reading

Technology

AttivoERP Emerges as a Unified Force in Full-Service ERP — Covering Every Stage of the Business Journey

Published

on

By

The consolidation of The Attivo Group and AttivoERP into one unified brand marks a new chapter — one partner, one mission, every stage of the ERP journey.

CONYERS, Ga. and IRVINE, Calif. and PROVIDENCE, R.I. and PITTSBURGH, July 10, 2026 /PRNewswire/ — AttivoERP, a full-service Enterprise Resource Planning (ERP) consulting and implementation firm serving manufacturers, distributors, and small to mid-sized growing businesses, today announced the unification of its brand under a single identity: AttivoERP.

This move brings together several decades of consulting expertise and ERP specialization into one team, one brand, and one mission, supporting clients across every stage of the ERP lifecycle.

When the company was founded, it deliberately positioned itself as a consultancy rather than simply a software vendor. This reflected its commitment to working with clients from the very beginning of their software purchasing journey, helping them assess needs, make informed decisions, and achieve successful outcomes. Over time, Attivo has evolved well beyond its original role. While ERP implementation remains a core area of expertise, the company now plays a much broader role in supporting organizations through their digital transformation journeys, delivering a wide range of solutions and services that help businesses modernize, innovate, and grow.

One Partner, Every Stage of the ERP Journey

AttivoERP now steps forward as a single, unified partner offering full-service ERP support from first evaluation through long-term optimization.

The company works across many of the industry’s leading platforms, including:

AcumaticaMicrosoft Dynamics 365 Business CentralOracle NetSuiteSAP Business OneEnterpryzeExact Globe+

AttivoERP’s full-service offering spans the entire ERP lifecycle, including:

ERP Selection: Helping businesses identify the right platform for their needs.Implementation: End-to-end deployment support.Training: Through the Attivo Academy resource.Support: Provided through the Attivo TotalCare program.Optimization: Ongoing system refinement as businesses grow.ERP Recovery: Rescuing stalled or troubled implementations.Legacy System Support: Including Macola, Sage 100, Exact, and Dynamics GP.Cloud Hosting: Through the dedicated Attivo Cloud Hosting.Specialized Integrations & Industry Add-Ons: Tailored to specific verticals and workflows.

“Today’s businesses require more than software support—they need a trusted advisor who understands their goals and helps them continuously improve,” said Len Reo, President & Founder of AttivoERP “Our brand relaunch, new website, and reinforces our commitment to innovation and to helping clients achieve lasting ERP success.

“The refreshed brand reflects AttivoERP’s evolution from a traditional ERP reseller and implementation partner into a strategic advisor focused on helping organizations achieve long-term business success through the alignment of people, processes, and technology.

“Len Reo, President & Founder of AttivoERP continued, “Whether a business is choosing their first ERP system or optimizing one they’ve run for a decade, they’re working with the same team, the same standards, and the same commitment to their success as when we first launched. This unification simply makes that visible from the outside.”

More Than Three Decades in the Making

AttivoERP’s roots trace back to 1992, when the company was founded as The Attivo Group — a consulting firm built around a simple idea: helping businesses run better. As ERP solutions became increasingly central to that mission, the business evolved, adopting the AttivoERP identity roughly six years ago to reflect the growing software and implementation focus.

Today, AttivoERP emerges as a unified whole: one brand, one presence, one team that has always worked toward the same goal, even under different names. This unification reflects 34 years of continuous improvement through more platforms, deeper expertise, and a growing team and partner network built around client success.

After more than three decades of growing, adapting, and expanding what we’re capable of, we’re stepping into the market as one unified brand, because that’s what we’ve become,” Reo added.

What’s New Alongside the Launch

The brand unification arrives alongside several new developments:

A new brand identity and unified website, launching this summer at attivoerp.com.AI-powered implementation and migration tools, designed to make ERP projects faster, more accurate, and more affordable.Attivo TotalCare, formalized as a new subscription offering within AttivoERP’s full-service approach.

The launch of AttivoERP.com provides a modern digital experience where clients and prospective customers can access solutions, resources, industry expertise, and educational content designed to maximize the value of their ERP investments.

“A unified brand needed a unified digital presence to match,” said Marla Malkin, VP of Marketing at AttivoERP. “Our new website and identity are built to make it immediately clear who we are and how we can help, no matter where a business is in their ERP journey.”

“For our team, this launch is more about how we show up for clients going forward,” said Emily Perez, Marketing Manager at AttivoERP. “Clients will see one consistent brand at every touchpoint, from the first conversation through years of ongoing support.”

About AttivoERP

AttivoERP is a leading Enterprise Resource Planning (ERP) company. AttivoERP is an ERP success partner that helps organizations align technology, people, and processes to drive operational excellence and sustainable growth. The company helps organizations streamline operations, improve visibility, automate business processes, and support growth through innovative technology solutions, strategic guidance, implementation services, managed services, and ongoing client success programs. 

For more information, visit www.AttivoERP.com.

Media Contact:
Marla Malkin
(949) 543-0935

View original content to download multimedia:https://www.prnewswire.com/news-releases/attivoerp-emerges-as-a-unified-force-in-full-service-erp–covering-every-stage-of-the-business-journey-302823021.html

SOURCE The Attivo Group

Continue Reading

Trending